Abstract
Capecitabine is a fluoropyrimidine chemotherapy prodrug of 5-fluorouracil (5-FU) used in the treatment of metastatic breast and colorectal cancers. Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is a rare side effect of capecitabine therapy, with eight cases previously reported. We report a case of DI-SCLE in a patient with a documented history of systemic lupus erythematosus (SLE). This is the second documented case of DI-SCLE in a patient with a past medical history of SLE, and provides evidence that there may be an increased risk of DI-SCLE in these patients. Further research should examine whether patients with SLE are at greater risk for this adverse event.
Highlights
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is characterized by histopathological and immunopathological features of typical SCLE that are induced by a drug, dissipate with the drug’s removal, and recur with reexposure to the agent.[1]
3 Here we present a case of DI-SCLE in association with capecitabine in the setting of known systemic lupus erythematosus (SLE)
One other patient had a history of SLE, making this the second case of DI-SCLE from capecitabine in the setting of underlying SLE and highlighting a potential association.[6]
Summary
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is characterized by histopathological and immunopathological features of typical SCLE that are induced by a drug, dissipate with the drug’s removal, and recur with reexposure to the agent.[1]. Dermatologic conditions commonly associated with capecitabine include palmar-plantar erythrodysesthesia, photoeruption, dermatitis, leopard-like vitiligo, erythematous rash, and onycholysis. 3 Here we present a case of DI-SCLE in association with capecitabine in the setting of known systemic lupus erythematosus (SLE)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
